Ascendis shows combination therapy benefits in achondroplasia trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia
April 8, 2026 8:01 AM EDT- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community
- Enhanced improvements in spinal canal dimensions observed with TransCon CNP and TransCon hGH combination therapy compared to TransCon CNP monotherapy
- For the TransCon CNP treatment-naïve cohort, the improvement in tibial femoral angle (TFA) indicated enhanced straightening of the legs
- Children treated with long-term TransCon CNP monotherapy maintained TFA in normal range in COACH
COPENHAGEN, Denmark, April 08, 2026... More
